Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion has submitted an IND amendment application to South Korea’s MFDS for the Phase 3 clinical trial of CT-P51 (Keytruda biosimilar) to adjust the number of trial subjects following a revision in its regulatory approval strategy.
📊 [Key Disclosure Details & Financial Summary]
- Disclosure Title: Application for Amendment of Phase 3 Clinical Trial Plan for CT-P51 (Keytruda Biosimilar) in Korea
- Filing Date & Regulatory Agency: March 30, 2026, Ministry of Food and Drug Safety (MFDS), South Korea
- Clinical Trial Phase: Global Phase 3
- Target Indication: Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Clinical Trial Title: A randomized, double-blind, active-controlled, parallel-group Phase 3 study to compare the efficacy and safety of CT-P51 versus Keytruda in combination with platinum-pemetrexed chemotherapy in previously untreated patients with metastatic non-squamous non-small cell lung cancer
- Trial Registration Number: EU CT number 2024-514048-98-00
- Trial Design & Duration:
- Number of Subjects: Undisclosed (Withheld for business confidentiality until regulatory approval)
- Treatment Duration: 2 years
- Design: Double-blind, randomized, active-controlled Phase 3 study
- Reason for Amendment: Adjustment of subject count due to revision in regulatory approval strategy
- Board Resolution / Fact Confirmation Date: March 30, 2026 (Filing date of the IND amendment)
- Withheld Information: Number of clinical trial subjects (Withheld for business confidentiality until IND amendment approval)
- Investment Caution: Statistically, the final approval rate for clinical drug candidates is approximately 10%. Unforeseen results during trial or approval stages may lead to changes or cancellation of commercialization plans.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of MFDS Approval and Subsequent Disclosure of Subject Count
This disclosure details Celltrion’s IND amendment application for CT-P51 submitted to the MFDS, making it essential to monitor for regulatory approval decisions. Tracking the regulatory decision is necessary because the currently withheld subject count will be publicly disclosed upon approval of the amendment. Approval outcomes and updated trial parameters can be verified through future regulatory disclosures or under ‘Ongoing Research and Development Activities’ in upcoming periodic filings (Quarterly, Half-Yearly, or Annual Business Reports).
📢 Disclaimer & Source Information
Source: This content was newly generated and structured based on official data submitted to the Data Analysis, Retrieval and Transfer System (DART) of the Financial Supervisory Service.
Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
